PRISM BioLab (206A) · TargetRestated
Stock Acquisition Rights for Directors and Audit & Supervisory Board Members Subject to Sales Exceeding ¥1 Billion
First written in FY2025-H1. 1 of 2 entries say "Restated". Latest entry: FY2025.
2entries
1years
0from disclosures
How it moved
Same theme, other companies
Exercise Conditions for Performance-Linked Stock Acquisition Rights for Officers and EmployeesA theme 178 companies write about · 9 as a headwind · 207 as a tailwind
26 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 159 companies compared. The sentences above are computed from all 159.Comparing 200 of the theme's 221 threads.Full recordFilings, disclosures and news, newest first
- FY2025RestatedAnnual report
「If revenue stated in our income statement (or consolidated income statement if we prepare one) exceeds ¥1,000 million even once during the fiscal years ending September 2026 through September 2028, these stock acquisition rights may be exercised.」
There has been no change to the terms of the stock acquisition rights for directors and audit & supervisory board members, which are conditional on revenue exceeding ¥1,000 million. - FY2025-H1First statedAnnual report
「If revenue stated in our income statement (or consolidated income statement if we prepare one) exceeds ¥1,000 million even once during the fiscal years ending September 2026 through September 2028, these stock acquisition rights may be exercised.」
For the 19th series of stock acquisition rights granted to 2 directors and 4 audit & supervisory board members, revenue exceeding ¥1,000 million in any of the fiscal years ending September 2026 through September 2028 has been established as an exercise condition.